risperidone and Childhood Tic Disorders studies

Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.

Research Excerpts

Excerpt	Relevance	Reference
"To investigate the association between hyperprolactinemia and variants of the dopamine D2 receptor (DRD2) gene in children and adolescents in long-term treatment with risperidone."	7.75	Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. ( Acion, L; Calarge, CA; Ellingrod, VL; Miller, DD; Moline, J; Schlechte, JA; Tansey, MJ, 2009)
"To investigate the association between hyperprolactinemia and variants of the dopamine D2 receptor (DRD2) gene in children and adolescents in long-term treatment with risperidone."	3.75	Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. ( Acion, L; Calarge, CA; Ellingrod, VL; Miller, DD; Moline, J; Schlechte, JA; Tansey, MJ, 2009)
"Despite the fact that psychiatric illness in the pre-adult era is not rare, few controlled clinical trials have examined the short-term safety and efficacy of these agents in youths with psychosis."	2.39	Antipsychotic medications in children and adolescents. ( Findling, RL; Grcevich, SJ; Lopez, I; Schulz, SC, 1996)
"Risperidone and clonidine were the most commonly recommended medications for tic disorders over the study period, with 36,868 and 35,500 recommendations in 2016, respectively."	1.51	Prescriptions for Alpha Agonists and Antipsychotics in Children and Youth with Tic Disorders: A Pharmacoepidemiologic Study. ( Cothros, N; Martino, D; McMorris, C; Pringsheim, T; Stewart, D; Tehrani, A, 2019)
"We used a systematic survey to collate the consensus of Japanese experts and compare it with the recent international evidence."	1.51	Expert consensus on pharmacotherapy for tic disorders in Japan. ( Fujio, M; Hamamoto, Y; Kano, Y; Kono, T; Matsuda, N; Nonaka, M, 2019)
"Risperidone was prevalent in younger, male patients with disruptive behavioral disorders; aripiprazole, in patients with tic disorders."	1.43	Persistence in Therapy With Risperidone and Aripiprazole in Pediatric Outpatients: A 2-Year Naturalistic Comparison. ( Antoniazzi, S; Auricchio, F; Bernardini, R; Bertella, S; Bravaccio, C; Capuano, A; Carnovale, C; Cattaneo, D; Clementi, E; Ferrajolo, C; Gentili, M; Guastella, G; Mani, E; Molteni, M; Pascotto, A; Pisano, S; Pozzi, M; Radice, S; Rafaniello, C; Riccio, MP; Rizzo, R; Rossi, F; Scuderi, MG; Sperandeo, S; Sportiello, L; Villa, L, 2016)
" Side effects were carefully monitored using adverse event evaluation charts."	1.33	Effectiveness and safety of risperidone for children and adolescents with chronic tic or tourette disorders in Korea. ( Cho, SC; Hwang, JW; Kim, BN; Lee, CB; Shin, MS, 2005)
""B" was an 11-year-old girl with mild mental retardation and aggression who was treated with risperidone 1 mg per day."	1.32	Risperidone-induced obsessive-compulsive symptoms in two children. ( Avci, A; Diler, RS; Scahill, L; Yolga, A, 2003)
"Risperidone has been proved on efficacy for tic disorders but EPS still remain, even though it was claimed to be less."	1.31	Quetiapine for tic disorder: a case report. ( Boonyanaruthee, V; Chan-Ob, T; Kuntawongse, N, 2001)
"The sample included five patients with Tourette's syndrome and two with chronic motor tic disorder."	1.29	Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. ( Chappell, PB; King, RA; Leckman, JF; Lombroso, PJ; Lynch, KA; McDougle, CJ; Peterson, BS; Scahill, L, 1995)

Research

Studies (23)

Authors

Clinical Trials (4)

Trial Overview

Trial Outcomes

Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	5 (21.74)	18.2507
2000's	10 (43.48)	29.6817
2010's	7 (30.43)	24.3611
2020's	1 (4.35)	2.80

Authors	Studies
Roessner, V	4
Eichele, H	1
Stern, JS	1
Skov, L	1
Rizzo, R	2
Debes, NM	1
Nagy, P	1
Cavanna, AE	1
Termine, C	1
Ganos, C	1
Münchau, A	2
Szejko, N	1
Cath, D	1
Müller-Vahl, KR	1
Verdellen, C	1
Hartmann, A	1
Rothenberger, A	2
Hoekstra, PJ	1
Plessen, KJ	1
Cothros, N	1
Martino, D	1
McMorris, C	1
Stewart, D	1
Tehrani, A	1
Pringsheim, T	1
Hamamoto, Y	1
Fujio, M	1
Nonaka, M	1
Matsuda, N	1
Kono, T	1
Kano, Y	1
Margari, L	1
Matera, E	1
Craig, F	1
Petruzzelli, MG	1
Palmieri, VO	1
Pastore, A	1
Margari, F	1
Ghanizadeh, A	1
Haghighi, A	1
Bachmann, CJ	1
Glaeske, G	1
Hoffmann, F	1
Pozzi, M	1
Pisano, S	1
Bertella, S	1
Capuano, A	1
Antoniazzi, S	1
Auricchio, F	1
Carnovale, C	1
Cattaneo, D	1
Ferrajolo, C	1
Gentili, M	1
Guastella, G	1
Mani, E	1
Rafaniello, C	1
Riccio, MP	1
Scuderi, MG	1
Sperandeo, S	1
Sportiello, L	1
Villa, L	1
Radice, S	1
Clementi, E	1
Rossi, F	1
Pascotto, A	1
Bernardini, R	1
Molteni, M	1
Bravaccio, C	1
Calarge, CA	1
Ellingrod, VL	1
Acion, L	1
Miller, DD	1
Moline, J	1
Tansey, MJ	1
Schlechte, JA	1
Schoenefeld, K	1
Buse, J	1
Bender, S	1
Ehrlich, S	1
Listernick, R	1
Diler, RS	1
Yolga, A	1
Avci, A	1
Scahill, L	2
Gilbert, DL	1
Batterson, JR	1
Sethuraman, G	1
Sallee, FR	1
Findling, RL	2
McNamara, NK	1
Banaschewski, T	1
Kim, BN	1
Lee, CB	1
Hwang, JW	1
Shin, MS	1
Cho, SC	1
Bloch, MH	1
Landeros-Weisenberger, A	1
Kelmendi, B	1
Coric, V	1
Bracken, MB	1
Leckman, JF	2
Su, JA	1
Tsang, HY	1
Chou, SY	1
Chung, PC	1
McDougle, CJ	2
Goodman, WK	1
Price, LH	1
Lombroso, PJ	1
King, RA	1
Lynch, KA	1
Chappell, PB	1
Peterson, BS	1
Diantoniis, MR	1
Henry, KM	1
Partridge, PA	1
Soucar, E	1
Grcevich, SJ	1
Lopez, I	1
Schulz, SC	1
Rowan, AB	1
Malone, RP	1
Chan-Ob, T	1
Kuntawongse, N	1
Boonyanaruthee, V	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Quetiapine Augmentation Versus Clomipramine Augmentation of Selective Serotonin Reuptake Inhibitors for Obsessive-compulsive Disorder Patients That do Not Respond to a SSRI Trial: a Randomized Open-trial.[NCT00564564]	Phase 4	21 participants (Actual)	Interventional	2006-01-31	Completed
Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)[NCT02422290]	Phase 1/Phase 2	5 participants (Actual)	Interventional	2015-03-31	Completed
An Open-Label Trial of Epidiolex in the Treatment of Obsessive Compulsive Disorder and Related Disorders: Proof of Concept Study[NCT04978428]	Phase 2	15 participants (Anticipated)	Interventional	2022-04-14	Recruiting
Open Label Study for the Use of Transcranial Ultrasound Treatment of Obsessive-Compulsive Disorder[NCT04775875]		30 participants (Anticipated)	Interventional	2020-12-01	Enrolling by invitation
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The CY-BOCS is a semi-structured measure of OCD severity with excellent inter-rater reliability, internal consistency, and test-retest reliability. It is validated in those starting at age 7 and used in studies up to age 20. The CYBOCS differs from the adult YBOCS only in its use of simpler language. The CY-BOCS consists of 10 items which are summed up to derive the total CY-BOCS score. The total score ranges from 0-40 with higher scores indicating greater severity of OCD symptoms. (NCT02422290)
Timeframe: Screening, Baseline, Day 7, Day 17, 3-Month; Baseline and Day 14 pre-specified to be reported

Clinical Global Impressions - Severity Scale (CGI-S)

Intervention	score on a scale (Mean)
	CY-BOCS Baseline	CY-BOCS Day 14
Ketamine Treatment Group	29.00	26.20

The CGI-S is a clinician rated 7-point rating scale for the severity of a participant's illness relative to the clinician's experience of working with this particular population. The score ranges from 1-7 with higher scores indicating greater illness severity. (NCT02422290)
Timeframe: Screening, Baseline, Day 7, Day 17, 3-Month; Baseline and Day 14 pre-specified to be reported

OCD Visual Analogue Scale (OCD-VAS)

Intervention	score on a scale (Mean)
	CGI-S Baseline	CGI-S Day 14
Ketamine Treatment Group	5.80	5.00

"The OCD-VAS is a one-item unipolar scale to assess OCD symptoms over a rapid time frame (No obsessions to Constant obsessions). The scale ranges from 0-10 with higher scores indicating higher presence of obsessions." (NCT02422290)
Timeframe: Screening, Baseline, Day 1-14, 3-Month; Baseline and Day 14 pre-specified to be reported

Yale-Brown Obsessive Compulsive Challenge Scale (Y-BOCCS)

Intervention	score on a scale (Mean)
	OCD-VAS Baseline	OCD-VAS Day 14
Ketamine Treatment Group	5.00	5.00

"The Y-BOCCS is self-report scale which assesses OCD symptoms on a 5-point likert scale (None to Extreme). It consists of 10 items which are summed up to derive the total Y-BOCCS score. The total score ranges from 0-40 with higher scores indicating higher prevalence of OCD symptoms." (NCT02422290)
Timeframe: Screening, Baseline, Day 1-14, 3-Month; Baseline and Day 14 pre-specified to be reported

Article	Year
European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment. European child & adolescent psychiatry, 2022, Volume: 31, Issue:3 Topics: Adult; Attention Deficit Disorder with Hyperactivity; Child; Female; Guanfacine; Humans; Male; Rispe	2022
Pharmacological treatment of tic disorders and Tourette Syndrome. Neuropharmacology, 2013, Volume: 68 Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivi	2013
Atypical antipsychotics in the treatment of children and adolescents: clinical applications. The Journal of clinical psychiatry, 2004, Volume: 65 Suppl 6 Topics: Adolescent; Age Factors; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders;	2004
[Therapy of tic-disorders]. Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie, 2004, Volume: 32, Issue:4 Topics: Antipsychotic Agents; Behavior Therapy; Benzamides; Child; Clonidine; Combined Modality Therapy; Hum	2004
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular psychiatry, 2006, Volume: 11, Issue:7 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive	2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular psychiatry, 2006, Volume: 11, Issue:7 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive	2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular psychiatry, 2006, Volume: 11, Issue:7 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive	2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular psychiatry, 2006, Volume: 11, Issue:7 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive	2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular psychiatry, 2006, Volume: 11, Issue:7 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive	2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular psychiatry, 2006, Volume: 11, Issue:7 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive	2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular psychiatry, 2006, Volume: 11, Issue:7 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive	2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular psychiatry, 2006, Volume: 11, Issue:7 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive	2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular psychiatry, 2006, Volume: 11, Issue:7 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive	2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular psychiatry, 2006, Volume: 11, Issue:7 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive	2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular psychiatry, 2006, Volume: 11, Issue:7 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive	2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular psychiatry, 2006, Volume: 11, Issue:7 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive	2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular psychiatry, 2006, Volume: 11, Issue:7 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive	2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular psychiatry, 2006, Volume: 11, Issue:7 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive	2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular psychiatry, 2006, Volume: 11, Issue:7 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive	2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular psychiatry, 2006, Volume: 11, Issue:7 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive	2006
Dopamine antagonists in tic-related and psychotic spectrum obsessive compulsive disorder. The Journal of clinical psychiatry, 1994, Volume: 55 Suppl Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Clomipramine; Clozapine; Dopamine Antagonists	1994
Antipsychotic medications in children and adolescents. The Journal of clinical psychiatry, 1996, Volume: 57 Suppl 9 Topics: Adolescent; Adult; Age Factors; Antipsychotic Agents; Autistic Disorder; Child; Child, Preschool; Cl	1996

Article	Year
Aripiprazole versus risperidone for treating children and adolescents with tic disorder: a randomized double blind clinical trial. Child psychiatry and human development, 2014, Volume: 45, Issue:5 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Double-Blind Method; Female; Humans; Male; Pi	2014
Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. Journal of the American Academy of Child and Adolescent Psychiatry, 2004, Volume: 43, Issue:2 Topics: Adolescent; Antipsychotic Agents; Child; Cross-Over Studies; Double-Blind Method; Female; Humans; Ma	2004
Tics and risperidone. Journal of the American Academy of Child and Adolescent Psychiatry, 1996, Volume: 35, Issue:7 Topics: Adolescent; Antipsychotic Agents; Child; Female; Humans; Male; Risperidone; Tic Disorders; Tourette	1996

Article	Year
Prescriptions for Alpha Agonists and Antipsychotics in Children and Youth with Tic Disorders: A Pharmacoepidemiologic Study. Tremor and other hyperkinetic movements (New York, N.Y.), 2019, Volume: 9 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Child, Preschool; Female; Guanfacine; Humans;	2019
Expert consensus on pharmacotherapy for tic disorders in Japan. Brain & development, 2019, Volume: 41, Issue:6 Topics: Adult; Aged; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Comorbidity; Consensus; Dr	2019
Tolerability and safety profile of risperidone in a sample of children and adolescents. International clinical psychopharmacology, 2013, Volume: 28, Issue:4 Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Body Composit	2013
Trends in psychopharmacologic treatment of tic disorders in children and adolescents in Germany. European child & adolescent psychiatry, 2015, Volume: 24, Issue:2 Topics: Adolescent; Adolescent Psychiatry; Antipsychotic Agents; Child; Child Psychiatry; Drug Prescriptions	2015
Persistence in Therapy With Risperidone and Aripiprazole in Pediatric Outpatients: A 2-Year Naturalistic Comparison. The Journal of clinical psychiatry, 2016, Volume: 77, Issue:12 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders;	2016
Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenetics and genomics, 2009, Volume: 19, Issue:5 Topics: Adolescent; Antipsychotic Agents; Child; Child Behavior Disorders; Female; Gene Frequency; Genetic P	2009
A nine-year-old girl with new-onset tics. Pediatric annals, 2003, Volume: 32, Issue:2 Topics: Antipsychotic Agents; Child; Chorea; Clonidine; Diagnosis, Differential; Female; Humans; Obsessive-C	2003
Risperidone-induced obsessive-compulsive symptoms in two children. Journal of child and adolescent psychopharmacology, 2003, Volume: 13 Suppl 1 Topics: Adult; Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Female; Huma	2003
Effectiveness and safety of risperidone for children and adolescents with chronic tic or tourette disorders in Korea. Journal of child and adolescent psychopharmacology, 2005, Volume: 15, Issue:2 Topics: Adolescent; Analysis of Variance; Child; Chronic Disease; Female; Humans; Korea; Male; Risperidone;	2005
Aripiprazole treatment for risperidone-associated tic movement: a case report. Progress in neuro-psychopharmacology & biological psychiatry, 2008, Apr-01, Volume: 32, Issue:3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Piperazines; Quinolones; Risperidone; Schiz	2008
Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. Journal of the American Academy of Child and Adolescent Psychiatry, 1995, Volume: 34, Issue:9 Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Child; Chronic Dise	1995
Tics with risperidone withdrawal. Journal of the American Academy of Child and Adolescent Psychiatry, 1997, Volume: 36, Issue:2 Topics: Antipsychotic Agents; Child; Dyskinesia, Drug-Induced; Humans; Male; Risperidone; Substance Withdraw	1997
Quetiapine for tic disorder: a case report. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2001, Volume: 84, Issue:11 Topics: Adult; Antipsychotic Agents; Dibenzothiazepines; Female; Haloperidol; Humans; Quetiapine Fumarate; R	2001

risperidone and Childhood Tic Disorders